arrow_back Back to App

Funding Cap for Arthritis, Musculoskeletal, and Skin Diseases Research 2024

This bill proposes to limit the available funds for the National Institute of Arthritis and Musculoskeletal and Skin Diseases for the fiscal year 2024. This means that research into these conditions might receive less money, potentially affecting the pace of developing new treatments and medications for individuals suffering from these diseases.
Key points
The bill sets a maximum funding amount for the National Institute of Arthritis and Musculoskeletal and Skin Diseases for fiscal year 2024 at $605,065,000.
Reduced funding could slow down progress in research for conditions like arthritis, osteoporosis, and skin diseases, impacting the availability of future treatments.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1986
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases for fiscal year 2024.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1986.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • The bill sets a maximum funding amount for the National Institute of Arthritis and Musculoskeletal and Skin Diseases for fiscal year 2024 at $605,065,000.
  • Reduced funding could slow down progress in research for conditions like arthritis, osteoporosis, and skin diseases, impacting the availability of future treatments.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health